Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer

Yoon Jae Kim, Daeil Sung, Eunhye Oh, Youngkwan Cho, Tae Min Cho, Lee Farrand, Jae Hong Seo, Ji Young Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Trastuzumab resistance is a multi-factorial phenomenon thought to arise from the presence of cancer stem cells and interactions between truncated p95HER2 and HER family members. Flubendazole (FLU) is a potent anthelmintic agent with an exceptional safety profile. Evidence also suggests that it can act as an anticancer agent in several cancer cell types. We sought to investigate the effect of FLU on apoptosis, HER2/Akt signaling, breast cancer stem cell (BCSC)-like properties and trastuzumab resistance in HER2-positive breast cancer cells. FLU treatment induced apoptosis, associated with a significant downregulation of truncated p95HER2, phospho-HER2, phospho-HER3 and phospho-Akt levels, as well as suppression of HER2/HER3 hetero-dimerization in both trastuzumab-sensitive and –resistant lines. FLU effectively targeted BCSC-like properties including aldehyde dehydrogenase 1 (ALDH1) expression and the CD44high/CD24low phenotype, concomitant with a suppression of mammosphere-forming ability. FLU administration also caused significant tumor suppression in trastuzumab-resistant xenografts, coinciding with the downregulation of BCSC-related markers and intracellular HER2. These findings highlight the mechanisms of action of FLU in overcoming trastuzumab resistance in breast cancer.

Original languageEnglish
Pages (from-to)118-130
Number of pages13
JournalCancer Letters
Volume412
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Neoplastic Stem Cells
Breast Neoplasms
Neoplasms
Down-Regulation
Apoptosis
Aptitude
Anthelmintics
Dimerization
Heterografts
Cell Communication
Antineoplastic Agents
flubendazole
Trastuzumab
Phenotype
Safety

Keywords

  • Cancer stem cells
  • Flubendazole
  • HER2
  • p95HER2
  • Trastuzumab resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. / Kim, Yoon Jae; Sung, Daeil; Oh, Eunhye; Cho, Youngkwan; Cho, Tae Min; Farrand, Lee; Seo, Jae Hong; Kim, Ji Young.

In: Cancer Letters, Vol. 412, 01.01.2018, p. 118-130.

Research output: Contribution to journalArticle

Kim, Yoon Jae ; Sung, Daeil ; Oh, Eunhye ; Cho, Youngkwan ; Cho, Tae Min ; Farrand, Lee ; Seo, Jae Hong ; Kim, Ji Young. / Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. In: Cancer Letters. 2018 ; Vol. 412. pp. 118-130.
@article{3eec4875577240549c373056183a0ab8,
title = "Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer",
abstract = "Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Trastuzumab resistance is a multi-factorial phenomenon thought to arise from the presence of cancer stem cells and interactions between truncated p95HER2 and HER family members. Flubendazole (FLU) is a potent anthelmintic agent with an exceptional safety profile. Evidence also suggests that it can act as an anticancer agent in several cancer cell types. We sought to investigate the effect of FLU on apoptosis, HER2/Akt signaling, breast cancer stem cell (BCSC)-like properties and trastuzumab resistance in HER2-positive breast cancer cells. FLU treatment induced apoptosis, associated with a significant downregulation of truncated p95HER2, phospho-HER2, phospho-HER3 and phospho-Akt levels, as well as suppression of HER2/HER3 hetero-dimerization in both trastuzumab-sensitive and –resistant lines. FLU effectively targeted BCSC-like properties including aldehyde dehydrogenase 1 (ALDH1) expression and the CD44high/CD24low phenotype, concomitant with a suppression of mammosphere-forming ability. FLU administration also caused significant tumor suppression in trastuzumab-resistant xenografts, coinciding with the downregulation of BCSC-related markers and intracellular HER2. These findings highlight the mechanisms of action of FLU in overcoming trastuzumab resistance in breast cancer.",
keywords = "Cancer stem cells, Flubendazole, HER2, p95HER2, Trastuzumab resistance",
author = "Kim, {Yoon Jae} and Daeil Sung and Eunhye Oh and Youngkwan Cho and Cho, {Tae Min} and Lee Farrand and Seo, {Jae Hong} and Kim, {Ji Young}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2017.10.020",
language = "English",
volume = "412",
pages = "118--130",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer

AU - Kim, Yoon Jae

AU - Sung, Daeil

AU - Oh, Eunhye

AU - Cho, Youngkwan

AU - Cho, Tae Min

AU - Farrand, Lee

AU - Seo, Jae Hong

AU - Kim, Ji Young

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Trastuzumab resistance is a multi-factorial phenomenon thought to arise from the presence of cancer stem cells and interactions between truncated p95HER2 and HER family members. Flubendazole (FLU) is a potent anthelmintic agent with an exceptional safety profile. Evidence also suggests that it can act as an anticancer agent in several cancer cell types. We sought to investigate the effect of FLU on apoptosis, HER2/Akt signaling, breast cancer stem cell (BCSC)-like properties and trastuzumab resistance in HER2-positive breast cancer cells. FLU treatment induced apoptosis, associated with a significant downregulation of truncated p95HER2, phospho-HER2, phospho-HER3 and phospho-Akt levels, as well as suppression of HER2/HER3 hetero-dimerization in both trastuzumab-sensitive and –resistant lines. FLU effectively targeted BCSC-like properties including aldehyde dehydrogenase 1 (ALDH1) expression and the CD44high/CD24low phenotype, concomitant with a suppression of mammosphere-forming ability. FLU administration also caused significant tumor suppression in trastuzumab-resistant xenografts, coinciding with the downregulation of BCSC-related markers and intracellular HER2. These findings highlight the mechanisms of action of FLU in overcoming trastuzumab resistance in breast cancer.

AB - Although trastuzumab provides significant clinical benefit for HER2-positive breast cancers, responses are limited by the emergence of resistance. Trastuzumab resistance is a multi-factorial phenomenon thought to arise from the presence of cancer stem cells and interactions between truncated p95HER2 and HER family members. Flubendazole (FLU) is a potent anthelmintic agent with an exceptional safety profile. Evidence also suggests that it can act as an anticancer agent in several cancer cell types. We sought to investigate the effect of FLU on apoptosis, HER2/Akt signaling, breast cancer stem cell (BCSC)-like properties and trastuzumab resistance in HER2-positive breast cancer cells. FLU treatment induced apoptosis, associated with a significant downregulation of truncated p95HER2, phospho-HER2, phospho-HER3 and phospho-Akt levels, as well as suppression of HER2/HER3 hetero-dimerization in both trastuzumab-sensitive and –resistant lines. FLU effectively targeted BCSC-like properties including aldehyde dehydrogenase 1 (ALDH1) expression and the CD44high/CD24low phenotype, concomitant with a suppression of mammosphere-forming ability. FLU administration also caused significant tumor suppression in trastuzumab-resistant xenografts, coinciding with the downregulation of BCSC-related markers and intracellular HER2. These findings highlight the mechanisms of action of FLU in overcoming trastuzumab resistance in breast cancer.

KW - Cancer stem cells

KW - Flubendazole

KW - HER2

KW - p95HER2

KW - Trastuzumab resistance

UR - http://www.scopus.com/inward/record.url?scp=85032678120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032678120&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.10.020

DO - 10.1016/j.canlet.2017.10.020

M3 - Article

C2 - 29080749

AN - SCOPUS:85032678120

VL - 412

SP - 118

EP - 130

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -